N-Isopropyl-2-methylindolin | 33555-44-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-Isopropyl-2-methylindolin
• 英文别名: 1-(1-methylethyl)-2-methyl-indoline；1-Isopropyl-2-methylindoline；2-methyl-1-propan-2-yl-2,3-dihydroindole
• CAS: 33555-44-1
• 化学式: C₁₂H₁₇N
• 分子量: 175.274
• InChiKey: TZOCRWHEFLRIJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-Isopropyl-2-methylindolin 生成 1-(1-Methylethyl)-2-methyl-indoline-5-carbaldehyde
  参考文献：
  名称：

  Mono-or polyenic carboxylic acid derivatives

  摘要：

  公式为##STR1##的化合物和公式为##STR2##的化合物或它们的盐具有与视黄酸受体结合的强大能力，因此在治疗牛皮癣和类风湿性关节炎方面非常有用。

  公开号：

  US05977125A1

文献信息

• PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20140206686A1

  公开（公告）日：2014-07-24

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了Formula (I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性的ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• EIS INHIBITORS
  申请人：University of Kentucky Research Foundation

  公开号：US20180162867A1

  公开（公告）日：2018-06-14

  Compounds and compositions are disclosed, which are useful as inhibitors of acetyltransferase Eis, a mediator of kanamycin resistance in Mycobacterium tuberculosis.

  揭示了作为乙酰转移酶Eis抑制剂的化合物和组合物，该酶是结核分枝杆菌中卡那霉素抗性的介质。
• [EN] COMPOUNDS AS RAS INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DE RAS ET LEURS UTILISATIONS
  申请人：BIOARDIS LLC

  公开号：WO2022087624A1

  公开（公告）日：2022-04-28

  The present disclosure relates generally to compounds and compositions thereof for inhibition of RAS, such as KRAS, HRAS and NRAS, including mutant forms of KRAS, HRAS and NRAS, particularly those harboring a G12C mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung cancer, colorectal cancer, pancreatic cancer, gall bladder cancer, thyroid cancer, and bile duct cancer.

  本公开涉及抑制RAS的化合物和其组成物，例如KRAS、HRAS和NRAS，包括带有G12C突变的KRAS、HRAS和NRAS的突变形式，制备这些化合物和组合物的方法，以及它们在治疗或预防各种癌症方面的用途，例如肺癌、结直肠癌、胰腺癌、胆囊癌、甲状腺癌和胆管癌。
• MONO- OR POLYENIC CARBOXYLIC ACID DERIVATIVE
  申请人：Eisai Co., Ltd.

  公开号：EP0790228A1

  公开（公告）日：1997-08-20

  To provide novel compounds relating to retinoid which can substitute for retinoic acid used for preventing and treating several diseases and having antagonism against retinoid. Heterocyclic compounds represented by the general formula (1-I) or physiologically acceptable salts thereof:         Z-(CR3=CR2)n-COOR1     (1-I) Compounds represented by the general formula (2-I) or physiologically acceptable salts thereof: The compounds according to the present invention exhibit extremely high ability to bind RARs and are effective for treating various kind of diseases such as abnormality in cornification and rheumatoid arthritis.

  提供与维甲酸有关的新型化合物，这些化合物可以替代用于预防和治疗多种疾病的维甲酸，并对维甲酸具有拮抗作用。 通式（1-I）代表的杂环化合物或其生理上可接受的盐类： Z-(CR3=CR2)n-COOR1 (1-I) 通式 (2-I) 所代表的化合物或其生理学上可接受的盐： 本发明的化合物具有极高的结合 RARs 的能力，可有效治疗各种疾病，如玉米粒化异常和类风湿性关节炎。
• Eis inhibitors
  申请人：University of Kentucky Research Foundation

  公开号：US10208000B2

  公开（公告）日：2019-02-19

  Provided herein are novel small-molecules that have use in the inhibition of Eis, which mediates kanamycin resistance in Mycobacterium tuberculosis. The presently-disclosed subject matter further includes a pharmaceutical composition including a small molecule inhibitor, as described herein, and a suitable pharmaceutical carrier. Methods of treating tuberculosis comprising administering to an individual an effective amount of the disclosed small molecule inhibitors to mediate kanamycin A resistance and treat tuberculosis are also provided.

  本文提供的新型小分子可用于抑制介导结核分枝杆菌卡那霉素耐药性的 Eis。目前公开的主题还包括一种药物组合物，其中包括本文所述的小分子抑制剂和合适的药物载体。还提供了治疗结核病的方法，包括向个体施用有效量的所公开的小分子抑制剂，以介导卡那霉素 A 抗性和治疗结核病。